Comparable stake leader
BlackRock, Inc.
SEC ownership of Protalix BioTherapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001006281.
Disclosed value leader
MAK Capital Fund LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- PLX on NYSE
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001006281
- Issuer location
- Hackensack, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Protalix BioTherapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
MAK Capital Fund LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 5%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 5%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
5%
MAK Capital Fund LP
4.5%
Gilad Mamlok
0%
RENAISSANCE TECHNOLOGIES LLC
1.4%
STATE STREET CORP
1.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
5%
|
$9,428,694
4,046,650 shares
|
$0 | 30 Jun 2026 |
| MAK Capital Fund LP |
13D/G
|
4.5%
|
$11,355,147
3,616,289 shares
|
-$3,244,593 | 24 Mar 2026 |
| Gilad Mamlok |
3/4/5
Sr. VP and CFO
|
0%
|
$7,770
3,631 shares
|
— | 24 Aug 2025 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
1.4%
|
$2,553,680
1,096,000 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
1.2%
|
$2,291,746
983,582 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.2%
|
$2,283,388
979,995 shares
|
— | 30 Jun 2026 |
| NORTHERN TRUST CORP |
13F
Company
|
1.1%
|
$2,149,053
922,340 shares
|
— | 30 Jun 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
0.63%
|
$1,189,789
510,639 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$101,046.
Buys
$101,360
Insiders: 1
Sells
$314
Insiders: 1
Net
+$101,046
Shares: +55,832
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 56,000
Shares: 168
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 56,000 | 168 | $101,360 | $314 | +$101,046 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Protalix BioTherapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Dexcel Pharma Technologies Ltd.
Net 12M change
+$101,046
Latest report
03 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Dexcel Pharma Technologies Ltd. | 10%+ Owner | $5,128,613 | Mixed | 02 Jun 2021 | ||
| Dror Bashan | PRESIDENT AND CEO, Director | $4,772,163 | +$101,360 | +2.2% | Mixed | 03 Sep 2026 |
| Eyal Rubin | Sr. VP and CFO | $931,882 | Mixed | 23 Sep 2024 | ||
| Aharon Schwartz | Director | $499,905 | Mixed | 03 Sep 2026 | ||
| Yaron Naos | Sr. VP & COO | $375,015 | Mixed | 03 Sep 2026 | ||
| Yael Hayon | VP, Research & Development | $49,512 | Mixed | 15 Aug 2023 | ||
| Amos Bar-Shalev | Director | $16,950 | -$314 | -1.8% | Mixed | 03 Sep 2026 |
| Eliot Forster | Director | $12,075 | Mixed | 03 Sep 2026 | ||
| Gwen A. Melincoff | Director | $12,075 | Mixed | 03 Sep 2026 | ||
| Christian Elze | Director | $12,075 | Mixed | 03 Sep 2026 | ||
| Zvi Shmuel Ben | Director | $12,075 | Mixed | 03 Sep 2026 | ||
| Pol F. Boudes | Director | $12,075 | Mixed | 03 Sep 2026 | ||
| Gilad Mamlok | Sr. VP and CFO | $7,770 | Mixed | 24 Aug 2025 | ||
| Zeev Bronfeld | Director | Mixed | 07 Sep 2022 |
Recent insider transactions for Protalix BioTherapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Aharon Schwartz | PLX | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Sep 2026 | Direct | |||
| Aharon Schwartz | PLX | Stock Options (Right to Buy) | Award | 17,000 | 17,000 | 03 Sep 2026 | Direct | |||
| Yaron Naos | PLX | Restricted Stock Units | Award | 56,000 | 56,000 | 03 Sep 2026 | Direct | |||
| Yaron Naos | PLX | Stock Option (Right to Buy) | Award | 112,000 | 112,000 | 03 Sep 2026 | Direct | |||
| Christian Elze | PLX | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Sep 2026 | Direct | |||
| Christian Elze | PLX | Stock Options (Right to Buy) | Award | 17,000 | 17,000 | 03 Sep 2026 | Direct | |||
| Gwen A. Melincoff | PLX | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Sep 2026 | Direct | |||
| Gwen A. Melincoff | PLX | Stock Options (Right to Buy) | Award | 17,000 | 17,000 | 03 Sep 2026 | Direct | |||
| Pol F. Boudes | PLX | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Sep 2026 | Direct | |||
| Pol F. Boudes | PLX | Stock Options (Right to Buy) | Award | 17,000 | 17,000 | 03 Sep 2026 | Direct | |||
| Dror Bashan | PLX | Restricted Stock Units | Award | 160,000 | 160,000 | 03 Sep 2026 | Direct | |||
| Dror Bashan | PLX | Stock Option (Right to Buy) | Award | 320,000 | 320,000 | 03 Sep 2026 | Direct | |||
| Amos Bar-Shalev | PLX | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Sep 2026 | Direct | |||
| Amos Bar-Shalev | PLX | Stock Options (Right to Buy) | Award | 17,000 | 17,000 | 03 Sep 2026 | Direct | |||
| Zvi Shmuel Ben | PLX | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Sep 2026 | Direct | |||
| Zvi Shmuel Ben | PLX | Stock Options (Right to Buy) | Award | 17,000 | 17,000 | 03 Sep 2026 | Direct | |||
| Eliot Forster | PLX | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Sep 2026 | Direct | |||
| Eliot Forster | PLX | Stock Options (Right to Buy) | Award | 17,000 | 17,000 | 03 Sep 2026 | Direct | |||
| Dror Bashan | PLX | Common Stock | Purchase | 42.3% | $101,360 | $1.81 | 56,000 | 188,516 | 19 Dec 2025 | Direct |
| Amos Bar-Shalev | PLX | Common Stock | Sale | -100% | $314 | $1.87 | -168 | 0 | 18 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.